Physician profile
Robert B Pendleton
NPI 1770556060
$6,460.23
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $550 · 2021: $2,338 · 2022: $894 · 2023: $1,162 · 2024: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,498.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $1,971.06 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $508.68 | 2019-2021 | |
| Alcon Vision LLC | $368.99 | 2019-2023 | Rocklatan, Hydrus Microstent |
| Regeneron Healthcare Solutions, INC. | $361.92 | 2019-2023 | Eylea, Eylea Hd |
| Mallinckrodt Hospital Products INC. | $320.49 | 2022-2024 | Acthar |
| Rxsight INC | $291.38 | 2021-2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Sight Sciences, INC. | $220.31 | 2019-2023 | Tearcare System |
| Johnson & Johnson Surgical Vision, INC. | $214.11 | 2020-2023 | Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $193.90 | 2020-2023 | |
| Lensar, INC. | $193.18 | 2019 | |
| Ivantis, INC | $167.98 | 2020-2021 | |
| Glaukos Corporation | $166.10 | 2019-2024 | Idose |
| Allergan, INC. | $156.16 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $117.07 | 2019-2021 | |
| Oyster Point Pharma, INC. | $115.23 | 2022-2024 | Tyrvaya |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $113.53 | 2022-2024 | Xiidra, Miebo, Vyzulta |
| Carl Zeiss Meditec, INC. | $107.59 | 2019 | |
| Abbvie INC. | $102.48 | 2022-2024 | |
| Thea Pharma INC. | $86.39 | 2022-2024 | Iyuzeh |
| Ani Pharmaceuticals, INC. | $76.81 | 2023 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $71.88 | 2023-2024 | Syfovre |
| Sun Pharmaceutical Industries INC. | $58.36 | 2019-2020 | |
| New World Medical,INC. | $54.45 | 2023 | |
| Genentech USA, INC. | $54.33 | 2023 | Vabysmo |
| Harrow Eye, LLC | $47.90 | 2023-2024 | Iheezo, Vevye |
| Horizon Therapeutics Plc | $47.77 | 2022-2023 | Tepezza |
| Eyepoint US, INC. | $42.04 | 2021 | |
| Optos, INC. | $39.42 | 2019 | |
| Ocular Therapeutix, INC. | $33.78 | 2020-2023 | Dextenza |
| Biotissue Holdings INC. | $30.68 | 2019-2024 | |
| Omeros Corporation | $30.00 | 2019-2021 | |
| Amgen INC. | $23.40 | 2024 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $17.07 | 2019 | |
| Astellas Pharma US INC | $15.47 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $14.70 | 2024 | |
| Notal Vision, INC. | $6.22 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pendleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.